Global pharmaceutical companies have been increasingly attempting to implement artificial intelligence (AI) and real world data (RWD) to the process of developing new drugs believing that using AI can drastically reduce the development period and maximize treatment efficacy. Global leaders in the pharmaceutical industry such as Pfizer, GlaxoSmithKline, Roche, AstraZeneca, and Novartis have been sparing no expense in investing in this area early on. Utilizing the data, they believe they can generate the same results in new drug development and clinical trials as traditional methods without incurring astronomical costs. The companies expect the clinical trials and the system would also change accordingly in the future.